Drug intelligence / Profile preview

EpiCeram

Development stage: Phase 4
Lead developer: Ceragenix Pharmaceuticals
Modality: Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Hydrogel Systems → Drug Delivery Systems
Administration: Topical

Overview

EpiCeram is a prescription-only, non-steroidal, controlled-release moisturizing skin-barrier emulsion indicated for the treatment of dry skin conditions and to manage and relieve burning and itching associated with various dermatoses, including atopic dermatitis, irritant contact dermatitis, and radiation dermatitis. Its mechanism of action is based on repairing the skin barrier through a unique tri-lipid formulation containing ceramide, cholesterol, and free fatty acids in an optimized 3:1:1 ratio that mimics the natural lipid composition of healthy skin. This formulation helps restore the stratum corneum’s integrity by replenishing essential lipids reduced in patients with eczema or atopic dermatitis. EpiCeram uses a proprietary MultiSal Encapsulation Delivery Technology to gradually deliver these physiological lipids over time for sustained barrier repair. It is steroid-free, fragrance-free, noncomedogenic, paraben-free, and propylene glycol-free[1][2][4][5][6].

Brand names: EpiCeram
Other names: EpiCeram Skin Barrier Emulsion

Beyond the preview

Go deeper on EpiCeram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EpiCeram.

Explore the full profile